With over 400 million chronic patients, India is among the world’s largest medication markets. However whereas most e-pharmacies chase pace, affordability stays the true problem. Truemeds took a special route: serving to sufferers change to lower-cost substitutes, a wager now paying off with new funding at about 4 occasions its earlier valuation.
The six-year-old startup has raised $85 million in a brand new spherical that features $65 million in major and $20 million in secondary funding led by Accel, together with participation from Peak XV Companions. TechCrunch first reported on Accel’s talks to again Truemeds final yr. Present buyers WestBridge Capital and InfoEdge Ventures, additionally participated.
The recent spherical has boosted Truemeds’ valuation to over $400 million, up from the $110 million in its final spherical two years in the past.
Based in 2019, Truemeds entered the market at a time when India’s on-line pharmacy house was already crowded with main gamers providing steep reductions on branded generics. However a few of these firms struggled to maintain early momentum — Prosus Ventures-backed PharmEasy, for example, noticed its valuation drop from a peak of $5.6 billion to under $600 million, whereas 1mg was acquired by Tata Digital, a part of the Tata Group. As an alternative of competing head-on, Truemeds’ founders selected to give attention to a comparatively area of interest phase: generic medicines.
“There is no such thing as a method to educate the person that you could have extra inexpensive choices for those who can’t afford these medicine,” stated Truemeds co-founder Akshat Nayyar (pictured above, left) in an interview. “That’s the place we felt that no one within the worth chain was working in the direction of that, and we are able to bridge that hole.”
The Mumbai-based recommends generic alternate options to customers for the branded medicines they want. This ultimately helps customers get monetary savings, as generic medicine are sometimes extra inexpensive than their branded variations on account of value efficiencies of their improvement course of.
Truemeds says its differentiated method has paid off, with income rising over 66% year-over-year to ₹5 billion ($57 million) within the final monetary yr. The startup says it retains greater than 15% of its income after 12 months and now serves a median of 500,000 prospects every month, with a complete of three million prospects up to now. Furthermore, it says it now serves over 20,000 postal codes throughout the nation, with greater than 75% of its prospects coming from tier-2 cities and past.
Techcrunch occasion
San Francisco
|
October 27-29, 2025
Nevertheless, educating prospects about alternate options to their prescribed medicines — and convincing them to change from branded medicine to generics — stays a problem.
“Since you get anchored to your prescribed model’s worth, and whenever you out of the blue see a cheaper price, you need to know why it’s low,” Nayyar instructed TechCrunch.
Growing reductions whereas rivals reduce
Whereas at the moment’s e-pharmacies chase pace over financial savings, the sector’s early playbook was completely different. On-line pharmacies in India used to supply reductions of as much as 25% to draw prospects. Nevertheless, Nayyar stated this dropped to twenty% after which 15% — the brand new common — as most burned money to accumulate new prospects and pivoted to sooner supply as their fundamental differentiator.
In the meantime, Truemeds has gone in the other way, growing its common reductions from 29% to 32% within the final 12 months. For a median person who switches manufacturers on the platform, financial savings attain 47% on their medication, says the corporate.
This comes from Truemeds’ deep procurement relationships with pharma firms, the place the startup makes use of its expertise to present producers higher demand visibility, serving to them plan manufacturing extra effectively for upcoming quarters, he stated.
The startup additionally depends by itself logistics in a few of the main cities it operates in and makes use of low-cost logistics companions for the remaining.
“We consider that our four-hour supply mannequin is greater than adequate from a persistent affected person’s perspective,” stated Nayyar. “You’re in a position to do extra deliberate purchases that approach, however we need to do it in probably the most environment friendly method, and go an increasing number of reductions to the top person reasonably than [focus on] the quickest supply for that matter.”
Subsequent up: AI-powered customization and doorstep diagnostics
As Truemeds must persuade prospects to decide on generics over branded medicines, it goes by deeper consultations with them. It already conducts 10-12 million consultations per yr. The startup has developed an algorithm through the years that appears at numerous parameters to exactly counsel alternate options to the branded medicine a buyer calls for. It considers nuances resembling whether or not the medication is sugar-coated whether it is for a younger affected person, the place it’s manufactured, and whether or not the plant is GMP-certified, amongst others. The startup additionally has a chatbot to handle some person queries rapidly.
Way more is on the roadmap. The corporate plans to develop an AI-based system that customizes conversations primarily based on prospects’ habits and former interactions with generic alternate options. It’s additionally opening a Bengaluru workplace whereas dedicating at the very least 20% of its capital to engineering and product improvement.
Past medicines, Truemeds is plotting to enter diagnostics by partnerships with nationwide pathology labs, planning to pilot lab testing providers in some tier-2 cities within the subsequent three to 4 months.
“The first mission stays the identical, which is making healthcare inexpensive for the top person,” the co-founder stated. “It began with medicines. Now that the mannequin is getting established, we’re going to maintain scaling that. Concurrently, we additionally need to see if we are able to do one thing comparable on the diagnostics entrance, the place we may be the bottom value supplier of at the very least the commonest checks.”
The startup additionally plans to extend its achievement middle rely by 300% — from 19 at present — over the subsequent 12 months, aiming to deepen its presence in present markets.
Earlier than this spherical, Truemeds raised $50 million and nonetheless has 30–35% of that capital within the financial institution, Nayyar stated.
The startup has a workforce of two,800 individuals, with 250 primarily based in its Mumbai workplace.